Sanofi Other Non-Current Liabilities 2010-2024 | SNY
Sanofi other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Sanofi other non-current liabilities for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
- Sanofi other non-current liabilities for 2023 were $10.763B, a 13.59% increase from 2022.
- Sanofi other non-current liabilities for 2022 were $9.476B, a 14.22% decline from 2021.
- Sanofi other non-current liabilities for 2021 were $11.047B, a 0.15% increase from 2020.
Sanofi Annual Other Non-Current Liabilities
(Millions of US $) |
| 2023 |
$10,763 |
| 2022 |
$9,476 |
| 2021 |
$11,047 |
| 2020 |
$11,030 |
| 2019 |
$11,008 |
| 2018 |
$11,309 |
| 2017 |
$11,506 |
| 2016 |
$11,301 |
| 2015 |
$11,426 |
| 2014 |
$14,238 |
| 2013 |
$12,777 |
| 2012 |
$15,930 |
| 2011 |
$16,271 |
| 2010 |
$12,899 |
| 2009 |
$11,591 |
Sanofi Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-09-30 |
|
| 2024-06-30 |
$11,517 |
| 2024-03-31 |
|
| 2023-12-31 |
$10,763 |
| 2023-09-30 |
|
| 2023-06-30 |
$10,445 |
| 2023-03-31 |
|
| 2022-12-31 |
$9,476 |
| 2022-09-30 |
|
| 2022-06-30 |
$9,527 |
| 2022-03-31 |
|
| 2021-09-30 |
|
| 2021-03-31 |
|
| 2020-09-30 |
|
| 2020-03-31 |
|
| 2019-09-30 |
|
| 2019-03-31 |
|
| 2018-03-31 |
|
| 2017-12-31 |
$11,506 |
| 2017-09-30 |
|
| 2017-06-30 |
$10,671 |
| 2017-03-31 |
|
| 2016-12-31 |
$11,301 |
| 2016-09-30 |
|
| 2016-06-30 |
$12,337 |
| 2016-03-31 |
|
| 2015-09-30 |
|
| 2015-06-30 |
$11,436 |
| 2014-06-30 |
$13,773 |
| 2013-06-30 |
$14,250 |
| 2012-06-30 |
$16,223 |
| 2012-03-31 |
|
| 2011-12-31 |
$16,271 |
| 2011-09-30 |
|
| 2011-06-30 |
$15,963 |
| 2011-03-31 |
|
| 2010-12-31 |
$12,899 |
| 2010-09-30 |
|
| 2010-06-30 |
$11,860 |
| 2010-03-31 |
|
| 2009-12-31 |
$11,591 |
| 2009-09-30 |
|
| 2009-06-30 |
$11,793 |
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$121.816B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
